- The pioneers and leader in Whole Genome Sequencing with one of the most accurate, highest quality and price competitive solutions on the market.
- Offering deep insights for consumers, universities, and the healthcare industry with best-in-class tools and interpretation capabilities.
“We believe we are destined to become a multibillion company. Our focused execution and smart diversification strategy have delivered stellar financial results, while the acquisition, licensing, and development of cutting-edge assets have billion-dollar potential. The best is yet to come.”
– Ted Karkus
ProPhase Labs is a next- generation biotech, genomics and diagnostics company focused on creating a healthier world through bold action and the power of insight. Find us on the Nasdaq, stock symbol PRPH.
We dream big and execute smartly through our diversified subsidiaries.
Delivered millions of highly accurate Upper Respiratory laboratory diagnostics, including PCR, antigen and flu tests in our state-of-the-art CLIA laboratories.LEARN MORE
- Developing groundbreaking compounds and products.
- Licensing and developing with the goal of commercializing Equivir (dietary supplement) and Equivir G (Rx), two broad based anti-virals.
- 30+ years of OTC manufacturing services and consumer healthcare product development from non-GMO, Organic and/or Natural-based cough drops and lozenges for over-the-counter drugs to dietary supplement products.
- Clinically-backed consumer products promoting better health, energy, and sexual vitality available online, Walmart, Walgreens, CVS, Rite-Aid and more.
We achieve extraordinary results with our focus on executional excellence, smart diversification, and a synergistic approach
Meet Our Management Team
Chairman & CEO
Ted Karkus, CEO and Chairman of ProPhase Labs, drives the company’s diverse and synergistic businesses with his successful track record in biomedical and health companies. He transformed ID Biomedical’s strategy and valuation from $25 million to $1.4 billion sale to GlaxoSmithKline. As CEO of ProPhase Labs, he restructured the go-to-market strategy for the ﬂagship product Cold-EEZE, turned around and significantly grew revenues, ultimately selling it for $50 million to Mylan.
ProPhase Labs is a fast-growing biotech, genomics and diagnostics company due to its commitment to growth, innovation, and execution excellence outlined in Ted’s high growth roadmap. He pivoted into industry leading CLIA labs, and then further diversified by acquiring genomics leader Nebula Genomics. Constantly innovating, Ted then created ProPhase BioPharma to deliver antivirals, cancer tests and therapeutic cancer compounds. The new acquisitions and legacy businesses work to drive synergistic growth with multi-billion-dollar potential.
He holds a BS in Psychology from Tufts University with Magna Cum Laude Honors and an MBA in Finance from Columbia University School of Business with Beta Gamma Sigma Honors.
Chief Operating Officer & Head of Finance Department
Jed A. Latkin served as a director and Chief Executive Officer of Navidea from October 2018, until October 2021. Mr. Latkin has more than 28 years of experience in the financial industry supporting many investments in major markets including biotechnology and pharmaceuticals. He most recently was employed by Nagel Avenue Capital, LLC since 2010, and in that capacity he provided contracted services as a CEO/CFO for numerous healthcare related firms. Mr. Latkin worked for over ten years in Investment Banking at Citigroup, Morgan Stanley and Fleet Boston Robertson Stephens. He also spent five years as a Co-Portfolio Manager for ING Investment Management. Mr. Latkin earned a B.A from Rutgers University and a M.B.A. from Columbia Business School.
Robert A Morse
Mr. Morse joined ProPhase Labs as Corporate Controller, served as Principal Financial Officer and Principal Accounting Officer prior to being promoted to CFO.
Prior to ProPhase Labs, Mr. Morse served as Global Controller and Chief Accounting Officer at multiple high-growth pre-IPO companies in the FinTech, EdTech and Asset Management sectors. Mr. Morse spent four years at MasterCard Worldwide and 10 years at The McGraw-Hill Companies and Standard & Poor’s. Mr. Morse began his career with four years in public accounting including two years with Ernst & Young LLP.
President, Nebula Genomics
Jason drove explosive revenue growth at ProPhase Diagnostics, leading multiple areas including sales, business development, logistics operations, and account management. He oversaw the development of two CLIA-certified labs, generating approximately $200 million in revenues since 2021 and manages account managers and customer service reps who offer 24/7 service to exceed customer expectations. Jason now heads up business development for the rapid build-out of ProPhase’s clinical and genomic businesses.
With a background in sales and development at top real estate firms, Jason is a graduate of the University of Maryland.
EVP/Chief Information Officer, ProPhase, Inc.
Sergio Miralles is an experienced IT Leader with over 12 years of experience in enterprise level Cybersecurity, Infrastructure, and Architecture. Sergio is responsible for ensuring a complete end-to-end technology solution that links its lab customers’ patient data via an interface to efﬁciently process and report results. Previously, Sergio founded and led a successful IT consulting ﬁrm overseeing 18 IT consultants. For the last five years, his primary focus has been on the medical, lab, and diagnostics business. Sergio holds several certiﬁcations from Cisco, ISC2, and CompTIA.
SVP, Director of Sales and Marketing, Nebula Genomics
Kamal is co-founder of Nebula Genomics. He received his undergraduate degree at Harvard University and did graduate studies in computer science as a Gates-Cambridge Fellow at the University of Cambridge. Prior to founding Nebula, Kamal led teams at Google. For his work, Kamal has received multiple honors including being named to the Forbes 30 under 30 list.